Pesquisas alternativas:
dose » dos (Expandir a Pesquisa)
develop » developed (Expandir a Pesquisa)
ther » them (Expandir a Pesquisa)
A mostrar 121 - 140 resultados de 3,991 para a pesquisa '(( ((drug dose) OR (drug dna)) develop type ) OR ( drug roles beyond ther ))*', tempo de pesquisa: 1.04seg Refinar resultados
Structural Analysis of the Simultaneous Activation and Inhibition of γ-Secretase Activity in the Development of Drugs for Alzheimer’s Disease
Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

T184. THE ROLE OF ADVERSE CHILDHOOD EXPERIENCES IN THE DEVELOPMENT OF A MORE SEVERE TYPE OF SCHIZOPHRENIA
DNA Methylation Bisubstrate Inhibitors Are Fast-Acting Drugs Active against Artemisinin-Resistant Plasmodium falciparum Parasites

Uracil-Directed Ligand Tethering: An Efficient Strategy for Uracil DNA Glycosylase (UNG) Inhibitor Development
Design and Evaluation of a Novel Matrix Type Multiple Units as Biphasic Gastroretentive Drug Delivery Systems

Aloe-emodin derived azoles as a new structural type of potential antibacterial agents: design, synthesis, and evaluation of the action on membrane, DNA, and MRSA DNA isomerase
Mining clinical big data for drug safety: Detecting inadequate treatment with a DNA sequence alignment algorithm

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a model‐based meta‐analytic approach
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

MutSα’s Multi-Domain Allosteric Response to Three DNA Damage Types Revealed by Machine Learning
An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening

Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates
Development of a Novel In Vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa